Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Payables (2019 - 2025)

aTYR PHARMA's Payables history spans 7 years, with the latest figure at $3.9 million for Q4 2025.

  • For Q4 2025, Payables fell 9.99% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $3.9 million, down 9.99%, while the annual FY2025 figure was $3.9 million, 9.99% down from the prior year.
  • Payables reached $3.9 million in Q4 2025 per ATYR's latest filing, down from $4.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $4.9 million in Q1 2024 to a low of $516000.0 in Q2 2023.
  • Average Payables over 5 years is $2.6 million, with a median of $2.7 million recorded in 2021.
  • Peak YoY movement for Payables: skyrocketed 268.82% in 2021, then tumbled 69.18% in 2023.
  • A 5-year view of Payables shows it stood at $1.0 million in 2021, then soared by 201.26% to $3.1 million in 2022, then grew by 13.62% to $3.5 million in 2023, then increased by 22.5% to $4.3 million in 2024, then dropped by 9.99% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Payables are $3.9 million (Q4 2025), $4.1 million (Q3 2025), and $3.9 million (Q2 2025).